DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lonaprisan
Lonaprisan
Tanibirumab (CUI C3490677) Add to Cart
Pushing Estrogen Receptor Around in Breast Cancer
Medical Treatment for Adenomyosis And/Or Adenomyoma
Expression Profiling of Nuclear Receptors in Breast Cancer Identifies TLX As a Mediator of Growth and Invasion in Triple-Negative Breast Cancer
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
University of Dundee Expression Profiling of Nuclear Receptors In
Selective Progesterone Receptor Modulators (Sprms): Progesterone Receptor Action, Mode of Action on the Endometrium and Treatment Options in Gynaecological Therapies
Antiprogestins in Gynecological Diseases
Pushing Estrogen Receptor Around in Breast Cancer
Management of Endometriosis: an Enigmatic Disease
Clormadinona ¿Todas Las Progestinas Son Iguales?
Steroid Hormone Receptors As Prognostic Markers in Breast Cancer
Antiprogestins in Breast Cancer Treatment: Are We Ready?
Pharmacology and Toxicology
Drug Design Approaches to Manipulate the Agonist-Antagonist
Current Status on Development of Steroids As Anticancer Agents
Top View
Pharmaabkommen A1 E
Hormonal Therapy for Endometriosis: from Molecular Research to Bedside
Sequentielle Verabreichung Von 20,20,21,21,21-Pentafluor-17-Hydroxy-1 1Beta-[4-(Hydroxyacetyl) Phenyl]-19-Nor-17Alpha-Pregna-4,9
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
A ACE Inhibitors. See Angiotensin-Converting Enzyme
(12) Patent Application Publication (10) Pub. No.: US 2014/0243254 A1 Hersel Et Al
Selective Progesterone Receptor Modulators in Early Stage Breast
Medical Treatment of the Endometriosis
Selective Progesterone Receptor Modulators in Gynaecological Therapies
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(12) United States Patent (10) Patent No.: US 9,631,013 B2 Modelska Et Al
The Anti-Tumourigenic Action of the Progesterone Receptor Antagonist
Bioinformatics Analysis of Essential Genes in NF1 and CDKN2A Null Cancer Cell Lines
Medical Treatment for Heavy Menstrual Bleeding
Endométriose : Briser Le Tabou Et Améliorer La Prise En Charge Apport Du Pharmacien D’Officine
Selective Progesterone Receptor
Bayer Annual Report 2008 Table of Contents
Oup Humupd Dmy020 577..598 ++
Clinical Study Synopsis